Tanox to Present at the Bear Stearns Healthcare Conference
August 31 2006 - 8:00AM
PR Newswire (US)
HOUSTON, Aug. 31 /PRNewswire-FirstCall/ -- Tanox, Inc.
(NASDAQ:TNOX) will deliver a company presentation at the 19th
Annual Bear Stearns Healthcare Conference Sept. 11-12, in New York
City. Tanox President and Chief Executive Officer Danong Chen,
Ph.D., will provide a company update and take investor questions at
the conference Sept. 11, at 10 a.m., EDT. A live webcast of the
presentation will be accessible from the Investor Relations section
on the company's Web site at http://www.tanox.com/ . Presentation
slides will be available on the site following the live address.
About Tanox, Inc. Tanox is a biotechnology company specializing in
the development of monoclonal antibodies. The company develops
innovative biotherapeutics for the treatment of immune-mediated
diseases, inflammation, infectious disease and cancer. Tanox's lead
investigational therapy, TNX-355, is a viral-entry inhibitor
antibody to treat HIV/AIDS. TNX-355 has shown significant antiviral
activity in Phase 2 clinical testing. Tanox's first-approved drug,
Xolair(R) (omalizumab), is the first antibody approved to treat
moderate-to-severe confirmed, allergic asthma. Xolair was developed
in collaboration with Genentech, Inc. and Novartis Pharma AG and is
approved for marketing in the United States, Canada and major
European countries. Tanox is based in Houston and has a
manufacturing facility in San Diego. Additional corporate
information is available at http://www.tanox.com/ .
http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGO DATASOURCE:
Tanox, Inc. CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211,
or Web site: http://www.tanox.com/
Copyright
Tanox (NASDAQ:TNOX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tanox (NASDAQ:TNOX)
Historical Stock Chart
From Oct 2023 to Oct 2024